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OBJECTIVE—This study was designed to determine whether
the transcription factor FoxM1 was required for regeneration of
-cell mass via proliferation and/or neogenesis in the adult after
60% partial pancreatectomy (PPx).
RESEARCH DESIGN AND METHODS—Adult mice with a
pancreas-wide deletion of Foxm1 (Foxm1
ﬂox/ﬂox;Pdx1-Cre
[FoxM1
panc]) and their control littermates (Foxm1
ﬂox/ﬂox) were
subjected to PPx or a sham operation, after which islet expres-
sion of Foxm1 and several target genes, -cell mass, prolifera-
tion, -cell size, islet size, islet density, and neurogenin-3
expression were analyzed.
RESULTS—In control mice, PPx stimulated -cell proliferation
and neogenesis and upregulated Foxm1 and several of its known
targets (Plk1, Cenp-a, Birc5/Survivin, and Ccnb1) in islets.
Within 1 week post-PPx, control mice underwent signiﬁcant
regeneration of -cell mass, and average islet size within the
regenerating lobe was similar to that after a sham operation.
However, FoxM1
panc mice exhibited speciﬁc impairments in
-cell mass regeneration and islet growth after PPx, with reduced
proliferation of - and -cells but no impairments in acinar or
ductal cell proliferation. Interestingly, FoxM1 was not required
for proliferation of -cells within small endocrine cell clusters
located in the regenerating portion of the pancreas but was
speciﬁcally required for proliferation of -cells within larger
islets. Additionally, FoxM1 was not required for -cell neogenesis
following PPx.
CONCLUSIONS—Our results indicate that FoxM1 is partially
required for increased -cell proliferation, but not -cell neogen-
esis, stimulated by PPx. Furthermore, FoxM1 seems to be
dispensable for proliferation of -cells following neogenesis but
is required for proliferation of preexisting -cells. Diabetes 57:
3069–3077, 2008
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s type 1 and type 2 diabetes result from abso-
lute or relative deﬁciencies in -cell number,
respectively, understanding how -cell number
is determined and can be manipulated may lead
to new therapeutic options. While transplantation of ca-
daveric islets remains promising, additional sources of
islets or -cells are required to make this treatment more
widely available (1). Diabetic patients would also beneﬁt
from in vivo manipulation of their -cell population.
-Cells proliferate slowly after birth (2), but increased
proliferation can be stimulated under various conditions,
including obesity, pregnancy, and growth factor overex-
pression (rev. in 3). In the adult mouse, -cell replication
is the primary mechanism by which new -cells are
formed (4,5). However, a recent study (6) in mice has
conclusively shown that new -cells are generated from
facultative adult progenitor cells (neogenesis) in response
to pancreatic injury, in a manner reminiscent of embryonic
endocrine cell differentiation. Furthermore, patients
with type 1 diabetes exhibit evidence for continued
-cell production in the face of immune destruction
(7,8), providing support for the ability of human -cells
to regenerate.
We previously showed that the forkhead box transcrip-
tion factor FoxM1 regulates postnatal -cell proliferation
(9). In other tissues, FoxM1 transactivates genes that
coordinate the G1/S and G2/M transitions, karyokinesis,
and cytokinesis (10,11). For example, the FoxM1 targets
Cdc25A and Cdc25B (cell division cycle 25 homolog A and
B, respectively) dephosphorylate and activate cyclin-
dependent kinase 2 (Cdk2) and Cdk1, respectively (12).
Cdk1 activity also depends on its binding to CcnB1 (cyclin
B1), another FoxM1 target (12,13). Additional targets
include S-phase kinase-associated protein 2 (Skp2) and
Cdk subunit 1 (Cks1), components of the SCF (Skp1-
Cullin1-F box) ubiquitin ligase complex that mediates
degradation of the Cdk inhibitors p21
Cip1, p27
Kip1, and
p57
Kip2 (14). FoxM1 also directly activates transcription of
polo-like kinase 1 (Plk1) (15), aurora B kinase, centromere
protein A (Cenp-A), Cenp-B, and survivin (Birc5) (14).
Plk1 is necessary for centrosome duplication and, with
aurora B kinase, mediates attachment of the microtubule
spindles to kinetochores. Survivin regulates aurora B
kinase centromere localization, while Cenp-A and -B are
involved in kinetochore assembly.
Although all proliferating cells express FoxM1, certain
cell types are more profoundly affected than others by
Foxm1 deletion. Foxm1
/ mice die during late embryo-
genesis due to hepatic and cardiac defects (16). Addition-
ally, pancreas-wide Foxm1 deletion (Foxm1
ﬂox/ﬂox;
Pdx1
5.5kb-Cre [FoxM1
panc]) does not affect embryonic
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-cell mass expansion via reduced -cell proliferation,
resulting in progressive diabetes in male mice (9). These
outcomes mirror those reported for widespread deletion
of other cell cycle regulators (Cdk4 and cyclin D), with
endocrine cell–speciﬁc effects causing diabetes (17–19).
Female FoxM1
panc mice remain glucose tolerant despite
signiﬁcantly reduced -cell mass and thus are the focus
of this study, allowing for analysis of -cell proliferation
and regeneration without the confounding effects of
hyperglycemia.
To determine whether FoxM1 is required for -cell regen-
eration, we performed 60% partial pancreatectomy (PPx) on
adult female FoxM1
panc and control (Foxm1
ﬂox/ﬂox) litter-
mates. Here, we show that Foxm1 and some of its tran-
scriptional targets were upregulated within islets
following PPx during the period of peak regeneration and
that endocrine cell proliferation and regeneration of -cell
mass following PPx were speciﬁcally impaired in
FoxM1
panc mice. Furthermore, we present evidence that
loss of FoxM1 did not impair islet neogenesis but did
impair islet growth after PPx.
RESEARCH DESIGN AND METHODS
Foxm1
ﬂox/ﬂox mice on a mixed background (129SvJ, C57BL/6) were described
previously (12). Brieﬂy, loxP sequences ﬂank exons 4–7, yielding a null allele
after Cre-mediated recombination. Pdx1
5.5kb-Cre mice (on a mixed ICR, CBA,
and C57BL/6 background) were generously provided by Guoqiang Gu (Vander-
bilt University) (20) and express Cre recombinase throughout the Pdx1
domain, including the entire pancreatic epithelium, by embryonic day (e) 10.5
(21,22). Foxm1 and Cre were genotyped as described (9,20). Rosa26-FoxM1
transgenic (Tg) mice (on a mixed FVB/N, C57BL/6 background) were previ-
ously described (23) and genotyped (as in 24). For embryonic analyses, the
morning of vaginal plug was considered e0.5. All mice received food and drink
ad libitum and were on a 12-h light-dark cycle. All mouse studies were
performed in accordance with the Vanderbilt Institutional Animal Care and
Use Committee guidelines under the supervision of the Division of Animal
Care.
Sixty percent PPx and intraperitoneal glucose tolerance test. Eight-
week-old female mice were anesthetized using isoﬂurane. A midline abdom-
inal incision allowed exteriorization of the splenic lobe of the pancreas
(between the gastroduodenal junction and the spleen). Sixty percent PPx was
performed by gently denuding the pancreatic tissue from the splenic lobe
using cotton-tipped swabs soaked in 0.9% saline, leaving the main pancreatic
duct and splenic artery intact. For sham operations, the splenic lobe was
isolated using cotton-tipped swabs and gently rubbed with a moistened gloved
ﬁnger for 1 min. Abdominal muscles were sutured using 5-0 vicryl (Ethicon),
and the skin was stapled using 9.0-mm staples (Reﬂex Skin Closure Systems).
A total of 0.1 mg/kg buprenorphine-HCl in normal saline was injected
subcutaneously for analgesia, and 0.8 mg/ml bromo-deoxyuridine (BrdU)
(Sigma-Aldrich) was administered in drinking water in a light-safe bottle and
was replaced on the 4th day. Mice were killed 1 week postoperation by
cervical dislocation, and the splenic and duodenal lobes of the pancreas were
harvested and analyzed separately. One day before and 7 days after the
operation, intraperitoneal glucose tolerance tests (IPGTTs) were performed
as described previously (9) (see Fig. 1 for experimental timeline).
RNA isolation and real-time quantitative RT-PCR. RNA from whole
pancreas or freshly isolated islets was extracted and DNase treated using the
RNAqueous and Turbo DNA-free kits (Ambion). RNA was assessed using the
ND-1000 Spectrophotometer (NanoDrop) and the 2100 Electrophoresis Bio-
analyzer (Agilent). cDNA was generated from 20 ng RNA using the Superscript
III First-Strand Synthesis System for RT-PCR (Invitrogen). Real-time PCR was
performed using the iQ5 Real-Time PCR Detection System (Bio-Rad) with iQ
Real-Time SYBR Green PCR Supermix (Bio-Rad) and the primer sets listed in
online appendix Table S1 (available at http://dx.doi.org/10.2337/db08-0878).
Results were quantitated using the Ct method.
Tissue preparation and histology. Pancreatic tissue was ﬁxed in 4%
paraformaldehyde for 2–4 h at 4°C, processed for parafﬁn embedding, and
sectioned at 5 m. Primary antibodies (guinea pig anti-insulin or anti-glucagon
[both 1:1,000; Linco], rabbit anti-cytokeratin [1:1,000; DakoCytomation], rat
anti-BrdU [1:400; Accurate Chemical and Scientiﬁc], rabbit anti–phospho-
histone H3 [1:250; Upstate Cell Signaling Solutions], and mouse anti–neuro-
genin-3 [Ngn3] [1:100; Developmental Studies Hybridoma Bank, University of
Iowa]) were incubated overnight at 4°C. Secondary antibodies (peroxidase-
conjugated donkey anti–guinea pig [1:250; Jackson Laboratories] and Cy2- or
Cy3-conjugated donkey anti–guinea pig, anti-rabbit, or anti-rat [all 1:500;
Jackson Laboratories]) were incubated for1ha troom temperature. Detection
of cytokeratin required pretreatment with 20 g/ml proteinase-K for 5 min at
room temperature, and detection of Ngn3 required microwave antigen re-
trieval with 10 mmol/l Tris-EGTA, pH 9.0, and tyramide signal ampliﬁcation
with TSA Kit no. 2 (Invitrogen).
-Cell mass analysis. Sections 250 m apart (5–15 sections per sample)
were incubated with anti-insulin primary antibody followed by peroxidase-
conjugated secondary antibody, visualized using a DAB Peroxidase Substrate
Kit (Vector Laboratories), and counterstained with eosin. Digital images were
created using a Nikon Coolscan 9000 and NikonScan version 4.0.2. Total
pancreatic and insulin
 areas of each section were measured using Meta-
Morph version 6.1 (Molecular Devices). -Cell mass equaled the ratio of total
insulin
 area to total pancreatic area of all sections, multiplied by tissue wet
weight.
Proliferation analyses. Sections 250–750 m apart (three to eight sections
per sample) were labeled with anti-insulin and anti-BrdU primary antibodies.
Nuclei were labeled with 1.5 g/ml 4,6-diamidino-2-phenylindole (DAPI)
(Molecular Probes) in mounting media. All insulin
 cells on each section were
imaged at 400 magniﬁcation on an Olympus BX41 microscope with a digital
camera using Magnaﬁre (Optronics). Percent proliferating -cells equaled the
number of insulin/BrdU double-positive cells divided by the total number of
insulin
 cells. -Cell proliferation was measured similarly, using anti-glucagon
labeling. Ductal cells were identiﬁed by cytokeratin labeling on sections
250–750 m apart, and images were captured at 200 magniﬁcation. Acinar
cells were identiﬁed by morphological characteristics on three separate 200
images from sections 750 m apart. BrdU labeling was previously described
(9). Phospho-histone H3 labeling of sections 125 m apart (seven to nine
sections per sample) required microwave antigen retrieval in 10 mmol/l
sodium citrate, pH 6.5, followed by 0.2% Triton-X-100 in PBS.
Islet, -cell, and nuclear size analyses. Using images collected for -cell
proliferation, the cross-sectional area of each insulin
 cell grouping was
circumscribed and measured using MetaMorph. Average cross-sectional -cell
size per islet equaled the total area of the islet divided by the number of -cell
nuclei within it. -Cell nuclear size was measured by circumscribing the
DAPI
 cross-sectional area within insulin
 cells.
Statistical analyses. Data were analyzed by unpaired t test or two-way
ANOVA with Bonferroni’s posttests, as appropriate, using GraphPad Prism
version 5.01. P 	 0.05 was considered signiﬁcant. Speciﬁc analyses performed
and sample sizes are included in the ﬁgure legends.
RESULTS
Sixty percent PPx upregulated Foxm1 and select
targets within islets while maintaining normo-
glycemia. FoxM1 mRNA and protein are relatively low in
adult islets (data not shown and 9), but it was unknown
whether upregulation occurs upon stimulation of endo-
crine cell proliferation. Indeed, Foxm1 expression was
upregulated twofold in control islets 6 days following PPx
versus sham (Fig. 2), suggesting that FoxM1 plays a role in
the regenerative response of endocrine cells. Importantly,
Foxm1 upregulation corresponded with the peak of -cell
proliferation following PPx (25).
FIG. 1. Experimental timeline for 60% PPx. Either PPx or a sham
operation was performed on 8-week-old female mice, after which BrdU
was administered in the drinking water for 1 week. IPGTT was per-
formed 1 day before and 7 days following the operation, and the mice
were killed on day 7.
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known FoxM1 targets, including Plk1, Cenp-a, Birc5/
survivin, and Ccnb1 (Fig. 2). Other targets, including
Skp2, Cks1, and Cdc25b, displayed a trend of upregula-
tion following PPx versus sham but did not reach
signiﬁcance. A similar trend was observed for Ccna2 but
not for Ccnd2, both of which have been linked to -cell
proliferation (17,18,26), but neither of which is a known
FoxM1 target.
To determine whether FoxM1 is necessary for endo-
crine cell regeneration following pancreatic injury,
FoxM1
panc and control female littermates underwent PPx
or sham operation at 8 weeks of age. Previous reports
showed that 60% PPx does not induce hyperglycemia (25),
unlike 90% PPx (27). IPGTTs performed 7 days following
60% PPx or sham conﬁrmed that control and FoxM1
panc
female mice remained glucose tolerant (Fig. 3).
Regeneration of -cell mass within the splenic lobe
was speciﬁcally impaired in FoxM1
panc mice. Similar
to FoxM1
panc male mice (9), FoxM1
panc female mice
also exhibited 
50% reduced -cell mass at 9 weeks of age
compared with littermate controls (data not shown), al-
though FoxM1
panc female mice remained normoglycemic.
This 
50% reduction in -cell mass was evident in the
splenic, but not duodenal, lobe and was unchanged after a
sham operation (Fig. 4B and C). Total pancreatic weight
and weight of the individual lobes were not signiﬁcantly
different between control and FoxM1
panc mice (Fig. 4A)
(data not shown), indicating a speciﬁc defect in the
endocrine compartment of the pancreas. Consistent with
previous ﬁndings (28), a signiﬁcant majority of -cell mass
was located within the splenic versus duodenal lobe of
control mice after a sham operation (P 	 0.01).
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FIG. 2. Expression levels of Foxm1 mRNA and some of its targets were
upregulated following 60% PPx. Real-time quantitative RT-PCR was
performed on RNA extracted from isolated islets 6 days following
either PPx (f) or sham (). Error bars represent SE of the mean.
Unpaired t tests were used to measure signiﬁcance. *P < 0.05; **P <
0.01. n  4–6 per group.
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FIG. 3. Glucose tolerance was maintained following 60% PPx. No
signiﬁcant differences in blood glucose levels were observed in either
control or FoxM1
panc mice following PPx compared with sham at any
time point during IPGTT. Error bars represent SE. Two-way ANOVA
with Bonferroni’s posttests was used to measure signiﬁcance. n  5–7
per group. , control sham day 7; f, FoxM1
panc sham day 7; ‚, control
PPx day 7; Œ, FoxM1
panc PPx day 7.
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FIG. 4. Regeneration of -cell mass, but not gross pancreatic tissue, was
impaired in FoxM1
panc mice. A: Wet weight of the pancreatic splenic lobe
was measured immediately following (day 0) or 7 days after PPx or sham.
The majority of tissue was removed by PPx, and a moderate amount of
regeneration occurred within 7 days in both control () and FoxM1
panc
(f) mice. B: -Cell mass, which takes into account tissue wet weight, was
signiﬁcantly reduced within the splenic lobe of FoxM1
panc pancreata
after a sham operation, and regeneration of -cell mass was not observed
in FoxM1
panc mice following PPx. C: -Cell mass within the duodenal
lobe of FoxM1
panc pancreata was only signiﬁcantly reduced in compari-
son with control pancreata following PPx. Error bars represent SE.
Two-way ANOVA with Bonferroni’s posttests, comparing sham day 7
versus PPx day 0 and PPx day 0 versus PPx day 7, was used to measure
signiﬁcance. n  4–6 per group. ns, not signiﬁcant.
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DIABETES, VOL. 57, NOVEMBER 2008 3071FIG. 5. Proliferation of endocrine cells was impaired in FoxM1
panc mice following 60% PPx. BrdU incorporation (red) over 7 days was used as a marker of
cell proliferation. Double labeling with insulin (green) revealed low, basal levels of -cell proliferation within the splenic lobes following a sham operation
in both control (A) and FoxM1
panc (C) mice. PPx enhanced BrdU incorporation into all pancreatic cell types within the splenic lobe of control mice (B), but
incorporation into endocrine cells was reduced in FoxM1
panc mice (D). -Cell proliferation was quantiﬁed for both the splenic (E) and duodenal (F)
pancreatic lobes. -Cell proliferation within small endocrine cell clusters (eight or less -cells) after PPx versus sham was enhanced in the splenic lobes of
FoxM1
panc and control mice (G) but was not altered in the duodenal lobes (H). -Cell proliferation within deﬁnitive islets (nine or more -cells) after PPx
was enhanced in the splenic lobe of control mice, and this effect was partially inhibited in FoxM1
panc mice (I). PPx also signiﬁcantly stimulated -cell
proliferation within deﬁnitive islets in the duodenal lobe of control, but not FoxM1
panc, mice (J). -Cell proliferation within the splenic lobe of FoxM1
panc
pancreata (K) was also impaired in comparison with control pancreata following PPx. Error bars represent SE. Two-way ANOVA with Bonferroni’s posttests
was used to measure signiﬁcance. n  4–5 per group for -cell proliferation, n  3–4 per group for -cell proliferation. ns, not signiﬁcant. E–K: , control;
f, FoxM1
panc. (Please see http://dx.doi.org/10.2337/db08-0878 for a high-quality digital representation of this ﬁgure.)
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within 7 days a signiﬁcant and equivalent amount of tissue
regenerated in both FoxM1
panc and control mice (Fig. 4A)
(online appendix Fig. S1A–D), suggesting that overall
pancreas regeneration during this time period was not
impaired by Foxm1 deletion. -Cell mass regeneration
within the splenic lobe, however, was impaired in
FoxM1
panc mice, as -cell mass in these mice did not
signiﬁcantly increase within 7 days following PPx, in
contrast to control littermates (Fig. 4B).
-Cell proliferation was reduced in FoxM1
panc mice
after 60% PPx. Because -cells are replenished primarily
by self-replication (4), and FoxM1 is important for post-
natal -cell proliferation (9), it seemed likely that reduced
-cell proliferation contributed to impaired -cell mass
regeneration in FoxM1
panc mice. Indeed, PPx dramati-
cally stimulated -cell proliferation in both pancreatic
lobes of control mice, and these effects were signiﬁcantly
blunted in FoxM1
panc mice (Fig. 5A–F). Moreover, -cell
proliferation within the duodenal lobe of FoxM1
panc mice
did not signiﬁcantly increase after PPx.
-Cell proliferation in the splenic lobe of FoxM1
panc
mice did increase signiﬁcantly following PPx versus sham,
despite Foxm1 deletion (Fig. 5E), due to increased prolif-
eration within small endocrine cell clusters (eight or fewer
insulin
 cells) and deﬁnitive islets (nine or more insulin

cells) (Fig. 5G and I). However, -cell proliferation within
deﬁnitive islets was signiﬁcantly reduced in FoxM1
panc
versus control mice (Fig. 5I). Because there was no
signiﬁcant impairment in -cell proliferation in small en-
docrine cell clusters in FoxM1
panc mice, we hypothesized
that these clusters represented newly formed -cells that
did not require FoxM1 for proliferation. This hypothesis
was supported by the ﬁnding that embryonic -cell prolif-
eration did not require FoxM1 (online appendix Fig. S2A
and B). Additionally, proliferation of -cells within small
endocrine cell clusters after PPx was speciﬁcally stimu-
lated in the regenerating splenic (Fig. 5G), but not duode-
nal (Fig. 5H), lobe. We hypothesize that just as perinatal
-cells can proliferate in the absence of FoxM1, newly
differentiated -cells in the adult can undergo several
rounds of FoxM1-independent replication before switch-
ing to FoxM1-dependent proliferation.
PPx stimulated -cell proliferation within deﬁnitive is-
lets of control mice to the same extent (sevenfold) in both
the splenic and duodenal lobes versus sham (Fig. 5I and
J). Proliferation in the splenic lobe of FoxM1
panc mice
increased only ﬁvefold, while the increase within the
duodenal lobe did not reach signiﬁcance, suggesting that
proliferation of preexisting -cells was impaired in the
absence of FoxM1. The increased BrdU incorporation
observed within deﬁnitive islets in the splenic lobe of
FoxM1
panc mice 7 days after PPx versus sham (Fig. 5I)
may represent proliferation that occurred at an earlier
stage of new islet development. These results are summa-
rized in Table 1. -Cells similarly required FoxM1 for
PPx-stimulated proliferation (Fig. 5K). In contrast, acinar
and ductal cell proliferation was not impaired in
FoxM1
panc mice (online appendix Fig. S3A and B), reveal-
ing that FoxM1 is speciﬁcally required for endocrine cell
proliferation.
FoxM1
panc mice exhibited increased -cell and nu-
cleus size. Sham-operated FoxM1
panc mice exhibited
larger average -cell size in both pancreatic lobes (Fig. 6A
and B) versus control littermates, due in part to increased
-cell nucleus size (Fig. 6C and D). However, hypertrophy
also contributed, likely as a compensatory measure due to
reduced -cell number. PPx did not alter -cell size in
control mice. However, average -cell size was signiﬁ-
cantly reduced speciﬁcally within the splenic lobe of
FoxM1
panc mice after PPx, likely due to new -cell
formation.
Islet size in FoxM1
panc mice was reduced following
60% PPx. Although PPx reduced total -cell number
within the splenic lobe, islets present within this lobe 7
days after PPx were of the same average size as after the
sham operation in control mice (Fig. 7A). However,
FoxM1
panc islets were signiﬁcantly smaller 7 days after
PPx compared with sham. Similarly, the average islet size
within the duodenal lobe of control mice trended toward
an increase following PPx versus sham, but no expansion
was observed in FoxM1
panc mice (Fig. 7B). These data
suggest that Foxm1 deletion impairs islet growth after
PPx. Of note, islets within the splenic lobe of control mice
after sham operation averaged two times larger than islets
within the duodenal lobe (P 	 0.05), which may be due to
a greater proportion of small endocrine cell clusters
versus deﬁnitive islets normally found in the duodenal
versus splenic lobe (P 	 0.05) (Fig. 7C and D). Interest-
ingly, after PPx FoxM1
panc mice exhibited an increased
proportion of small endocrine cell clusters versus deﬁni-
tive islets within their splenic lobe in comparison with
control mice (Fig. 7C), which likely contributed to their
reduced average islet size. No differences were observed
in the proportion of small endocrine cell clusters between
control and FoxM1
panc mice after sham operation or
within the duodenal lobe under any condition (Fig. 7D).
-Cell neogenesis following 60% PPx was not im-
paired in FoxM1
panc mice. The average number of
insulin
 cell groupings in the splenic lobe of both
FoxM1
panc and control mice trended toward an in-
crease 7 days after PPx versus day 0 (Fig. 7E), while no
differences were observed in the duodenal lobes of
either genotype (Fig. 7F). Insulin
 cells were observed
within foci of regeneration in the splenic lobes of both
groups of mice (online appendix Fig. 1B and D), sug-
gesting that generation of new islets, or neogenesis,
occured speciﬁcally in the splenic lobe after PPx and
was not impaired in FoxM1
panc mice. These ﬁndings
were supported by observation of Ngn3, a marker of
TABLE 1
Summary of -cell proliferation results for control and
FoxM1
panc mice after sham versus PPx
-Cell
proliferation
in clusters
-Cell
proliferation
in islets
Control PPx versus sham
Splenic lobe 11
Duodenal lobe %1
FoxM1
panc PPx versus sham
Splenic lobe 11
Duodenal lobe %%
FoxM1
panc sham versus control
sham
Splenic lobe %%
Duodenal lobe %%
FoxM1
panc PPx versus control
PPx
Splenic lobe %2
Duodenal lobe %2
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DIABETES, VOL. 57, NOVEMBER 2008 3073endocrine progenitor cells (29), in ductal epithelial cells
in both control (Fig. 7G) and FoxM1
panc (Fig. 7H) mice
following PPx. Importantly, Ngn3 expression was only
observed in ductules within the regenerating portion of
the splenic lobe but not within differentiated pancreas
tissue. No difference in the number of Ngn3
 ductal
epithelial cells was detected between control and
FoxM1
panc mice following PPx.
Foxm1 overexpression did not enhance -cell mass
regeneration following 60% PPx. To determine
whether Foxm1 overexpression affects pancreas and
-cell regeneration following PPx, we utilized Rosa26-
FoxM1 Tg mice that constitutively and ubiquitously
overexpress human FoxM1 (23). Despite FoxM1 over-
expression within islets (online appendix Fig. S4A), Tg
mice exhibited no signiﬁcant differences in glucose
tolerance (online appendix Fig. S4B)o r-cell mass
following PPx (online appendix Fig. S4C) compared
with wild-type littermates. Furthermore, we observed
no differences in pancreatic tissue weight (online ap-
pendix Fig. S4D), average islet size (online appendix
Fig. S4E), or islet density (online appendix Fig. S4F)
between Tg and wild-type mice in either lobe.
DISCUSSION
FoxM1 is highly expressed within pancreatic endocrine
cells during embryogenesis and is downregulated with age
(9), corresponding with reduced -cell proliferation. We
previously showed that mice with Foxm1 deleted through-
out the pancreatic epithelium (FoxM1
panc) exhibit im-
paired growth and maintenance of postnatal -cell mass
secondary to reduced postnatal -cell proliferation, asso-
ciated with increased nuclear-localized p27
Kip1 and prema-
ture cellular senescence (9). Several of FoxM1’s direct
transcriptional targets inhibit p27
Kip1 by promoting its
ubiquitination and subsequent degradation (Skp2, Cks1)
(14) or its nuclear export (kinase-interacting stathmim)
(30). Here, we show that FoxM1
panc mice have impaired
-cell mass regeneration following PPx due to reduced
-cell proliferation but that neogenesis proceeds normally.
Sixty percent PPx is a normoglycemic pancreatic injury
model that stimulates regeneration by differentiation and
proliferation and hyperplasia of preexisting tissue. We
found that Foxm1 and some of its targets were upregu-
lated within islets following PPx during a period of en-
hanced - and -cell proliferation, and we hypothesized
that FoxM1 was required for injury-stimulated endocrine
cell proliferation. Indeed, we found that FoxM1
panc mice
exhibited impaired - and -cell proliferation and impaired
-cell mass regeneration following PPx. PPx stimulated
-cell proliferation in both the splenic (regenerating) and
duodenal (expanding) lobes of control mice but not in the
duodenal lobe of FoxM1
panc mice. Thus, hyperplasia of
preexisting -cells after injury requires FoxM1.
Interestingly, PPx-stimulated -cell proliferation was
blunted, but not completely inhibited within the splenic
lobe of FoxM1
panc mice, due at least in part to impaired
proliferation in deﬁnitive islets, but not small endocrine
cell clusters, in the absence of FoxM1. These data
suggest that another pathway(s), which may mimic that
utilized during embryonic pancreas development, com-
pensates for loss of FoxM1 during regeneration, as
FoxM1 was also not required for embryonic -cell
proliferation. Thus, preexisting -cells seemingly ex-
Sham Day 7 PPx Day 7
0
25
50
75
100
125
P<0.01
P<0.05
P<0.001
S
p
l
e
n
i
c
 
L
o
b
e
A
v
g
.
 
I
n
s
u
l
i
n
+
 
C
e
l
l
 
S
i
z
e
 
(
u
m
2
) A
Sham Day 7 PPx Day 7
0
25
50
75
100
125 P<0.001
B
D
u
o
d
e
n
a
l
 
L
o
b
e
A
v
g
.
 
I
n
s
u
l
i
n
+
 
C
e
l
l
 
S
i
z
e
 
(
u
m
2
)
Sham Day 7 PPx Day 7
0
10
20
30 P<0.01 P<0.01
S
p
l
e
n
i
c
 
L
o
b
e
A
v
g
.
 
β
-
C
e
l
l
 
N
u
c
l
e
a
r
 
S
i
z
e
 
(
u
m
2
) C
Sham Day 7 PPx Day 7
0
10
20
30
D
u
o
d
e
n
a
l
 
L
o
b
e
A
v
g
.
 
β
-
C
e
l
l
 
N
u
c
l
e
a
r
 
S
i
z
e
 
(
u
m
2
) D
FIG. 6. FoxM1
panc mice exhibited increased -cell and nucleus size. After a sham operation, FoxM1
panc mice exhibited increased -cell size in
both the splenic (A) and duodenal (B) pancreatic lobes. Increased -cell size was also observed after PPx in the splenic lobe of FoxM1
panc mice
versus controls but was signiﬁcantly reduced compared with after a sham operation. The average -cell size in control pancreata was unchanged
by PPx. FoxM1
panc mice also exhibited increased -cell nucleus size in the splenic (C) but not duodenal (D) lobe, which was unchanged by PPx.
Error bars represent SE. Two-way ANOVA with Bonferroni’s posttests was used to measure signiﬁcance. n  4–5 per group. , control; f,
FoxM1
panc.
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panc mice exhibited impaired islet growth but no impairment in islet neogenesis after 60% PPx. There was no signiﬁcant difference
in average islet size, measured as the cross-sectional area of each insulin
 cell grouping, between control () and FoxM1
panc (f) mice after a
sham operation or PPx in either the splenic (A) or duodenal (B) pancreatic lobes. Following PPx, the average islet size in the splenic lobe of
control pancreata was similar to that observed in sham-operated mice, but FoxM1
panc islets were signiﬁcantly reduced in size. Within the
duodenal lobe, control mice trended toward increased average islet size after PPx, but no increase was observed in FoxM1
panc mice. FoxM1
panc
mice speciﬁcally exhibited an increased proportion of small insulin
 cell clusters (one to eight -cells) within the splenic lobe after PPx (C); no
differences were observed within the duodenal lobe (D). f, more than eight -cells; , one to eight -cells. The number of insulin
 cell groupings
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formed by neogenesis. Although it is currently unclear
which factors are required for -cell proliferation during
embryogenesis and following islet neogenesis, our stud-
ies support the hypothesis that neogenesis in the adult is
similar to embryonic -cell development, both with
regard to reexpression of Ngn3 and initial FoxM1-
independent proliferation.
Because BrdU was administered over 7 days, we may
have underestimated the effects of Foxm1 deletion on
endocrine cell proliferation. Previous studies have
shown that Foxm1
/ cells can undergo multiple
rounds of DNA synthesis without karyo- or cytokinesis
(endoreduplication), resulting in polyploid nuclei (16).
We found evidence of polyploid -cells and exocrine
cells in FoxM1
panc mice. These cells would have been
counted as proliferating cells in our analyses but would
not have actually resulted in increased cell number. This
phenomenon could partially explain the increased BrdU
incorporation in -cells without signiﬁcant -cell mass
regeneration within the splenic lobe of FoxM1
panc mice
after PPx compared with sham, although it most likely
would not be restricted to one lobe.
Additionally, incomplete Foxm1 recombination could
have resulted in mosaic expression, allowing some
-cells to continue proliferating. However, we think that
this is unlikely because we previously showed that
Pdx1
5.5kb-Cre recombined the Rosa26-LacZ reporter
allele within all endodermally derived pancreatic cells
and yielded a signiﬁcant reduction in FoxM1 protein by
e15.5 (9). We also found that Foxm1 transcripts were
signiﬁcantly reduced in FoxM1
panc neonatal pancreas
(online appendix Fig. S5A) and even more dramatically
in adult islets (online appendix Fig. S5B). These tissues
contain nonendodermally derived mesenchymal, endo-
thelial, and neuronal cells, which would not undergo
Foxm1 recombination and thus likely account for re-
maining transcript expression.
Proliferation of - and -cells, but not acinar or ductal
cells, was reduced in FoxM1
panc mice versus control
littermates following PPx, suggesting that FoxM1 is re-
quired speciﬁcally within endocrine cells. These data
concur with other studies (17–19,31) showing that endo-
crine cells are particularly susceptible to perturbations in
cell cycle regulation. The current study utilized quantita-
tive RT-PCR on islet RNA to assess changes in Foxm1
expression following PPx. Unfortunately, antibodies to
detect FoxM1 protein in mouse tissue do not currently
exist, precluding precise identiﬁcation of the cell popula-
tion(s) in which FoxM1 expression or localization changes
with time and after PPx. Such studies will allow for better
understanding of cell type–speciﬁc requirements for
FoxM1 and may help to explain the differing effects of
FoxM1 absence that we observe between endocrine and
exocrine cells following PPx. However, our expression
analyses identiﬁed several potentially important regulators
of pancreatic endocrine cell proliferation and regeneration
that are themselves regulated by FoxM1 (Plk1, Cenp-a,
Birc5/survivin, and Ccnb1).
We also presented evidence of -cell neogenesis
following 60% PPx, including Ngn3
 duct cells, insulin

cells within regenerating tissue, and increased islet
density. These ﬁndings were equivalent between control
and FoxM1
panc mice, revealing that -cell neogenesis
does not require FoxM1. Peshavaria et al. (25) showed
increased small endocrine cell clusters by 2 days post-
PPx, which normalized by 7 days. Our data are consis-
tent with this ﬁnding, as control mice at 7 days post-PPx
exhibited a normal proportion of small endocrine cell
clusters. However, FoxM1
panc mice had an increased
proportion of small endocrine cell clusters at 7 days
post-PPx, indicating that formation of these clusters is
not impaired in the absence of FoxM1, but signiﬁcant
growth is. These data support our hypothesis that initial
proliferation of newly differentiated -cells does not
require FoxM1, but these cells later switch to a FoxM1-
dependent state. Unfortunately, current technology pre-
cludes real-time monitoring of -cell proliferation and
islet growth. However, this study highlights the impor-
tance of -cell proliferation as a mechanism of -cell
mass regeneration, as our data show that neogenesis,
without adequate proliferation, is not sufﬁcient to regen-
erate a signiﬁcant amount of -cell mass after 60% PPx.
As -cell regeneration after partial duct ligation mimics
embryonic -cell differentiation with Ngn3 reexpression
(6), it is not surprising that similar processes occur
following 60% PPx, although perhaps to a lesser extent.
Previous studies (5,32) asserting the lack of reactivation of
the embryonic program, and thus neogenesis, following
PPx were performed in a manner that likely precluded true
regeneration, with surgical excision of the splenic lobe
and pancreatic duct, while other studies (4) did not
analyze the splenic lobe speciﬁcally, possibly missing the
contribution of neogenesis and regeneration to new -cell
formation. The current study removed tissue from the
splenic lobe, leaving the main pancreatic duct intact. This
lobe was analyzed separately, and only speciﬁc foci of
regeneration exhibited evidence of neogenesis. Thus, this
study does not contradict but adds to the current knowl-
edge regarding the potential for pancreas regeneration and
-cell neogenesis.
FOXM1 overexpression did not affect -cell regenera-
tion following PPx, suggesting that FoxM1 is not sufﬁcient
to induce -cell proliferation, emphasizing that the -cell
cell cycle is under tight negative regulatory control, even
after injury. As reviewed (33), -cells express all of the cell
cycle “brakes” studied thus far but only some “accelera-
tors.” Thus, it may be more difﬁcult than initially antici-
pated to stimulate -cell proliferation in vivo or in vitro as
a therapeutic option for diabetic patients. Because FoxM1
positively regulates cell cycle accelerators and negatively
regulates cell cycle brakes, it is of particular interest.
However, better understanding of posttranslational and
inhibitory regulators is necessary to successfully manipu-
late FoxM1 activity in -cells.
per section was reduced within the splenic lobe of FoxM1
panc mice compared with control littermates after a sham operation (E), but at day 0
and day 7 following PPx, the number of insulin
 cell groupings per section was equivalent between FoxM1
panc and control mice. Seven days after
PPx, there was a trend in both groups of mice to show increased numbers of insulin
 cell groupings per section within the splenic lobe, but no
differences between any groups of mice were observed in the duodenal lobe (F). Ngn3 expression was detected only after PPx within cytokeratin

(CK
) ductal epithelial cells located within foci of regeneration in the splenic lobes of both control (G) and FoxM1
panc (H) mice. Error bars
represent SE. Two-way ANOVA with Bonferroni’s posttests was used to measure signiﬁcance. n  4–5 per group. (Please see http://dx.doi.org/
10.2337/db08-0878 for a high-quality digital representation of this ﬁgure.)
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